Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Pharmacoeconomics. 2018 Dec;36(12):1427-1437. doi: 10.1007/s40273-018-0677-7
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Pharmacoeconomics. 2018 Dec;36(12):1427-1437. doi: 10.1007/s40273-018-0677-7
Lancet 2018;391:2513–24
RMD Open. 2018 May 8;4(1):e000662. DOI: 10.1136/rmdopen-2018-000662
Rheumatol Ther. 2018 Dec;5(2):341-353. doi: 10.1007/s40744-018-0113-7
Pharmacoeconomics 2018 Jul; 36(7):769–78
Pharmacoeconomics 2018 Sep; 36(9): 1063–72
Arthritis Res Ther 2018; 20(1):60 doi: 10.1186/s13075-018-1539-6
Rheumatol Ther 2018 Jun; 5(1):203–14. DOI: 10.1007/s40744-018-0093-7
Rheumatology (Oxford) 2018 May; 57(5):900-908